Benitec Biopharma Inc.
BNTC
N/A
Change (1 day)
N/A
Year High
N/A
Year Low
Categories
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.
P/S ratio for Benitec Biopharma Inc. (BNTC)
P/S ratio as of 2024: 0.00
According to Benitec Biopharma Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.00. At the end of 2023 the company had a P/S ratio of 75.02.
P/S ratio history for Benitec Biopharma Inc. from 2013 to 2024
P/S ratio at the end of each year
| Year | P/S ratio |
|---|---|
| 2024 | 0.00 |
| 2023 | 75.02 |
| 2022 | 129.85 |
| 2021 | 309.41 |
| 2020 | 83.27 |
| 2019 | 1.22 |
| 2018 | 62.08 |
| 2017 | 46.80 |
| 2016 | 34.98 |
| 2015 | 97.00 |
| 2014 | 103.62 |
| 2013 | 52.00 |